Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

Just Posted

Faced with safety fears in Chinese community, Breed pins blame on Board of Supervisors

San Francisco’s Chinese community is deeply worried about crime, and Mayor London… Continue reading

Jurors replaced and deliberations set to begin again in Ghost Ship trial

Three jurors have been dismissed Monday in the trial of Ghost Ship… Continue reading

Suspect in Embarcadero attack surrenders to authorities on new allegations

Austin James Vincent has landed at the center of a battle over plans to build a homeless shelter

Rocks off! Rolling Stones sound great in Santa Clara

No Filter tour serves up classic hits

Gov. Gavin Newsom signs bill setting new standards for police use of force

Here’s how ‘Stephon Clark’s law’ sets California rules

Most Read